JTCS Medtronic Endurant
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Christine L. Lau
Irving L. Kron
Victor E. Laubach
Gorav Ailawadi
David J. Pinsky
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lau, C. L.
Right arrow Articles by Pinsky, D. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Lau, C. L.
Right arrow Articles by Pinsky, D. J.
Related Collections
Right arrow Lung - transplantation
Right arrow Lung - basic science

J Thorac Cardiovasc Surg 2009;137:1241-1248
© 2009 The American Association for Thoracic Surgery


Cardiothoracic Transplantation

Enhanced fibrinolysis protects against lung ischemia–reperfusion injury

Christine L. Lau, MDa, Yunge Zhao, MD, PhDa, Jiyoun Kim, PhDb, Irving L. Kron, MDa, Ashish Sharma, MBBSa, Zequan Yang, MD, PhDa, Victor E. Laubach, PhDa, Joel Linden, PhDc, Gorav Ailawadi, MDa,*, David J. Pinsky, MDd

a Division of Thoracic and Cardiovascular Surgery, University of Virginia, Charlottesville, Va
b Department of Pathology, Boston University, Boston, Mass
c Department of Internal Medicine, University of Virginia, Charlottesville, Va
d Department of Internal Medicine, Ann Arbor, Mich

Received for publication September 18, 2008; revisions received November 18, 2008; accepted for publication December 25, 2008.

* Address for reprints: Gorav Ailawadi, MD, PO Box 800679, Charlottesville, VA 22908-0679. (Email: GA3F{at}virginia.edu).

Objective: Ischemia–reperfusion injury continues to plague the field of lung transplantation, resulting in suboptimal outcomes. In acute lung injury, processes such as ventilator-induced injury, sepsis, or acute respiratory distress syndrome, extravascular fibrin has been shown to promote lung dysfunction and the acute inflammatory response. This study investigates the role of the fibrinolytic cascade in lung ischemia–reperfusion injury and investigates the interplay between the fibrinolytic system and the inflammatory response.

Methods: Mice lacking the plasminogen activator inhibitor-1 gene (PAI-1 knock out, PAI-1 KO; and thus increased lysis of endogenous fibrin) and wild-type mice underwent in situ left lung ischemia and reperfusion. Fibrin content in the lung was evaluated by immunoblotting. Reperfusion injury was assessed by histologic and physiologic parameters. Proinflammatory mediators were measured in bronchoalveolar lavage fluid and plasma using enzyme-linked immunosorbent assays.

Results: Ischemia–reperfusion causes fibrin deposition in murine lungs. Less fibrin was seen in PAI-1 KO mice than in wild-type mice subjected to the same ischemia–reperfusion conditions. By histologic criteria, more evidence of ischemia–reperfusion injury was noted (thickening of the interstium, cellular infiltration in the alveoli) in the wild-type than in PAI-1 KO mice. Physiologic parameters also revealed more ischemia–reperfusion injury in the wild-type than in PAI-1 KO mice. Cytokine and chemokines were elevated more in the wild-type group than the PAI-1 KO group.

Conclusions: Lung ischemia–reperfusion injury triggers fibrin deposition in the murine lungs and fibrin creates a proinflammatory environment. Preventing fibrin deposition may reduce ischemia–reperfusion injury and inflammation. This finding may lead to novel treatment strategies for ischemia–reperfusion.



Abbreviations and Acronyms BAL = bronchoalveolar lavage; ELISA = enzyme-linked immunosorbent assay; IR = ischemia–reperfusion; IRI = ischemia–reperfusion injury; KC = keratinocyte chemoattractant; KO = knock out; IL-10 = interleukin 10; MCP-1 = monocyte chemoattractant protein-1; MIP-2 = macrophage inflammatory protein-2; PAI-1 = plasminogen activator inhibitor-1; PCR = polymerase chain reaction; PE = polyethylene; RT-qPCR = real-time quantitative polymerase chain reaction; TNF-{alpha} = tumor necrosis factor-alpha; WT = wild type





This article has been cited by other articles:


Home page
ThoraxHome page
A. Goolaerts, M. Lafargue, Y. Song, B. Miyazawa, M. Arjomandi, M. Carles, J. Roux, M. Howard, D. A. Parks, K. E. Iles, et al.
PAI-1 is an essential component of the pulmonary host response during Pseudomonas aeruginosa pneumonia in mice
Thorax, September 1, 2011; 66(9): 788 - 796.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
Y. Zhao, A. K. Sharma, D. J. LaPar, I. L. Kron, G. Ailawadi, Y. Liu, D. R. Jones, V. E. Laubach, and C. L. Lau
Depletion of tissue plasminogen activator attenuates lung ischemia-reperfusion injury via inhibition of neutrophil extravasation
Am J Physiol Lung Cell Mol Physiol, May 1, 2011; 300(5): L718 - L729.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
H.-S. Shin, F. Xu, A. Bagchi, E. Herrup, A. Prakash, C. Valentine, H. Kulkarni, K. Wilhelmsen, S. Warren, and J. Hellman
Bacterial Lipoprotein TLR2 Agonists Broadly Modulate Endothelial Function and Coagulation Pathways In Vitro and In Vivo
J. Immunol., January 15, 2011; 186(2): 1119 - 1130.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2009 by The American Association for Thoracic Surgery.